AxoSim Technologies
1441 Canal Street
New Orleans
Louisiana
70112
United States
Tel: (504)-304-6229
Website: http://axosim.com/
Email: info@axosim.com
About AxoSim Technologies
AxoSim is the first organ-on-a-chip company to focus exclusively on the nervous system. AxoSim’s Nerve-On-A-Chip® platform predicts clinical performance from the benchtop, helping pharmaceutical and defense clients develop safer and more effective therapies, drugs, and countermeasures. This platform grows living human nerves in a proprietary 3D environment to provide a more accurate, efficient, and cost-effective alternative to animal testing compared to anything available on the market.
AxoSim’s Nerve-On-A-Chip® platform is the first-ever 3D in vitro model of the nervous system to deliver human-relevant data to predict clinical outcomes prior to human trials. Current platform applications test both safety, with our neurotoxicity model, and efficacy, using AxoSim’s custom disease models to mimic disease states such as MS and ALS.
6 articles about AxoSim Technologies
-
AxoSim Extends Leadership in Human Organoids for Neurological Drug Discovery with Acquisition of StemoniX microBrain™ Technology
10/24/2023
AxoSim, Inc. announced completion of its acquisition of the microBrain™ associated assets of Vyant Bio's StemoniX subsidiary.
-
AxoSim Enters Into a Definitive Agreement to Acquire Vyant Bio's StemoniX Assets
7/17/2023
AxoSim, Inc., a leader in the development and application of human biomimetic platforms for neurological diseases, and Vyant Bio, Inc. (OTC: VYNT) (Vyant Bio) today announced that they have entered into a definitive agreement under which AxoSim will acquire the microBrain™-associated assets of Vyant Bio's StemoniX subsidiary.
-
Publication Confirms AxoSim's Nerve-on-a-Chip® Technology Embodies Key Nervous System Functions Needed to Speed New Drug R&D
7/9/2019
First Biomimetic Model to Demonstrate Myelination of Human Nerve Cells with Human Schwann Cells
-
AxoSim Licenses Revolutionary Mini-Brain Technology from Johns Hopkins University Enabling the Use of Human Data to Speed New Drug Research
5/30/2019
AxoSim, Inc. announced an exclusive license from Johns Hopkins University to intellectual property underlying the "Mini-Brain" technology, which uses induced pluripotent stem cells to create functional models of the human brain.
-
AxoSim Leads a Biotech Startup Scene in New Orleans
8/29/2016
-
Up-and-Coming AxoSim Hiring Scientists After Landing Research Grants to Speed Research
8/15/2016